Tufts Center for the Study of Drug Development (CSDD) has been researching the outsourcing environment for the past 20 years. However, this new study puts a spotlight on a relatively new area of focus around oversight. The research aimed to measure and quantify perceived effectiveness in the critical outsourcing function. As organizations take a hard look at their current practices, the research findings provide valuable insight and actionable areas for improvement.

Join Ken Getz of Tufts CSDD as he discusses the results of the study and their implications. Specific areas covered include:

Approaches deployed for oversight
Overall effectiveness of these practices
Plans to improve oversight methods

The session will include a summary of the results from this groundbreaking survey that will inform the viewer of the myriad of outsourcing models used, outsourcing hierarchy utilized, and challenges faced due to inconsistency and lack of management involvement.

Speakers will also share their perspective on where the industry is headed and ways to overcome oversight challenges including transparency, risk, and compliance.

Keywords:

Speakers

Ken Getz, Director of Sponsored Research Programs & Associate Professor, Tufts CSDD

Kenneth A. Getz is the Director of Sponsored Research and an associate professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine. He is responsible for directing research programs on drug development management strategy and practice including protocol design and execution; outsourcing; investigative site management; and patient recruitment and retention. He is the chair of CISCRP – a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise. Ken is also the founder of CenterWatch, a leading publisher in the clinical trials industry.

Message Presenter

Julie Peacock, Client Services, Comprehend

Closely aligned with customers and the sales organization, Julie focuses on enabling prospects and customers on Comprehend’s Clinical Intelligence solutions. She manages go-to-market strategy, sales enablement, and product marketing.

Prior to Comprehend, Julie spent 18 years at Oracle Corporation in the enterprise application space where she managed strategy, field enablement and launch activities for a series of BtoB solutions. Julie holds a bachelor’s degree in Marketing from Auburn University.

Message Presenter

Who Should Attend?

CROs, Clinical Operations and Data Management Professionals

Clinical Trial/Clinical Study Management
Clinical Data/Informatics/IT
Clinical Outsourcing
Clinical Project Managers/Directors
Director of Project Delivery

Clinical Research, Technology and Business Professionals

Biometrics/Biostatistics
Business Technology/Applications/Solutions
Business Analyst
CTO
Project Management

What You Will Learn

Join Ken Getz of Tufts CSDD as he discusses the results of a recent study on oversight and their implications. Specific areas covered include:

Approaches deployed for oversight
Overall effectiveness of these practices
Plans to improve oversight methods

Xtalks Partners

The Tufts Center for the Study of Drug Development

The Tufts Center for the Study of Drug Development is an independent, academic, non-profit research group at Tufts University in Boston, Massachusetts. Its mission is to develop strategic information to help drug developers, regulators, and policymakers improve the quality and efficiency of pharmaceutical and biopharmaceutical development, review, and utilization.

Comprehend

Comprehend offers a suite of Clinical Intelligence applications that enables ClinOps Execs, Data Managers and Medical Monitors to significantly improve the speed, safety and quality of a portfolio of clinical trials Across studies, sites, systems and CROs, Comprehend’s Clinical Intelligence Suite is particularly effective for centralized monitoring, risk monitoring, CRO oversight and collaboration, and medical monitoring initiatives. Comprehend gives life sciences companies a new source of competitiveness and the confidence to deliver high quality trial submissions at a new speed. Comprehend: The speed to quality results. Learn more at www.comprehend.com.